Clinical Trials

300 enrolled

Neoplasms

NCT02521051 2025-05-13

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Phase 1/2 Terminated

11 enrolled 21 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

770 enrolled

Rare Tumor

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

72 enrolled

Phase NA Not yet recruiting

Neoplasm Metastasis

NCT06709274 2024-11-29

MOTION-NSCLC

342 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

90 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05015010 2024-08-09

ALNEO

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT05525338 2024-05-13

ADAPT ALEC

Phase 4 Recruiting

196 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

3,000 enrolled

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Phase EARLY_PHASE1 Withdrawn

Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05081674 2023-10-11

BLISS

Phase 2 Completed

154 enrolled

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03158389 2023-09-28

N²M²

Phase 1/2 Completed

228 enrolled

CNS

Glioblastoma

NCT03779191 2023-07-06

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Phase 2 Completed

41 enrolled

ALK Gene Rearrangement Positive

NCT05725200 2023-02-21

EVIDENT